<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03544229</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-906-2002</org_study_id>
    <secondary_id>2018-001275-21</secondary_id>
    <nct_id>NCT03544229</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of treatment with 2 dose&#xD;
      levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12&#xD;
      weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-906. TAK-906 is being tested to treat&#xD;
      people who have symptomatic idiopathic or diabetic gastroparesis.&#xD;
&#xD;
      The study will enroll approximately 205 patients. Participants will be randomly assigned (by&#xD;
      chance, like flipping a coin) to one of the three treatment groups (in 1:1:1 ratio) which&#xD;
      will remain undisclosed to the patient and study doctor during the study (unless there is an&#xD;
      urgent medical need):&#xD;
&#xD;
      TAK-906 Maleate 5 mg (After implementation of Amendment 8, participants will not be further&#xD;
      randomized to this arm) TAK-906 Maleate 25 mg TAK-906 Maleate 50 mg Placebo (dummy inactive&#xD;
      pill) - this is a capsule that looks like the study drug but has no active ingredient&#xD;
&#xD;
      Prior to Amendment 8, participants were randomized to receive TAK-906 5 mg. After&#xD;
      implementation of Amendment 8, participants will not be further randomized to this dose arm.&#xD;
      All participants will be asked to take one capsule twice daily, at approximately the same&#xD;
      time each day throughout the study.&#xD;
&#xD;
      This multi-center trial will be conducted worldwide. The overall study duration is&#xD;
      approximately 17 weeks. Participants will make multiple visits to the clinic, and will be&#xD;
      contacted by telephone 30 days after receiving their last dose of study drug for a follow-up&#xD;
      assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2018</start_date>
  <completion_date type="Actual">July 14, 2021</completion_date>
  <primary_completion_date type="Actual">June 14, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) Composite Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ANMS GCSI-DD composite score includes score of nausea, early satiety, upper abdominal pain and postprandial fullness. The severity scores of these symptoms range from 0 ( none) to 4 (very severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with At Least 50% Reduction From Baseline in ANMS GCSI-DD Composite Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ANMS GCSI-DD composite score includes score of nausea, early satiety, upper abdominal pain, and postprandial fullness. The severity scores of these symptoms range from 0 ( none) to 4 (very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the ANMS GCSI-DD Nausea Symptom Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ANMS GCSI-DD nausea symptom score ranges from 0-none to 4-very severe. High scores reflect greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the ANMS GCSI-DD Early Satiety Symptom Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ANMS GCSI-DD early satiety symptom score ranges from 0-none to 4-very severe. High scores reflect greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the ANMS GCSI-DD Postprandial Fullness Symptom Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ANMS GCSI-DD postprandial fullness symptom score ranges from 0-none to 4-very severe. High scores reflect greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the ANMS GCSI-DD Upper Abdominal Pain Symptom Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ANMS GCSI-DD upper abdominal pain symptom score ranges from 0-none to 4-very severe. High scores reflect greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the ANMS GCSI-DD Recorded Vomiting Frequency at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The vomiting score assesses the number of vomiting episodes during the day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the ANMS GCSI-DD Overall Severity of Gastroparesis Symptoms Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ANMS GCSI-DD gastroparesis symptoms score ranges from 0-none to 4-very severe. High scores reflect greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the ANMS GCSI-DD Bloating Severity Scale Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ANMS GCSI-DD bloating severity scale score ranges from 0-none to 4-very severe. High scores reflect greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the ANMS GCSI-DD Total Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ANMS GCSI-DD total score quantifies the incidence and severity of symptoms, specifically nausea, early satiety, postprandial fullness, upper abdominal pain, bloating, and vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Symptomatic Weeks</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Symptomatic weeks are weeks with average composite symptom score assessed as &gt;mild [ANMS GCSI-DD score â‰¥2] during 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) Total Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation). Higher scores indicate higher symptom severity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Diabetic Gastroparesis</condition>
  <condition>Idiopathic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>TAK-906 Maleate 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-906 maleate 5 mg, capsules, orally, twice daily (BID) for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-906 Maleate 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-906 maleate 25 mg, capsules, orally, twice daily for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-906 Maleate 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-906 maleate 50 mg, capsules, orally, twice daily for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-906 maleate placebo-matching capsules, orally, twice daily for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-906 Maleate</intervention_name>
    <description>TAK-906 maleate capsules.</description>
    <arm_group_label>TAK-906 Maleate 25 mg</arm_group_label>
    <arm_group_label>TAK-906 Maleate 5 mg</arm_group_label>
    <arm_group_label>TAK-906 Maleate 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-906 Maleate Placebo</intervention_name>
    <description>TAK-906 maleate placebo-matching capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Should have experienced symptoms of gastroparesis (e.g., postprandial fullness,&#xD;
             nausea, vomiting, upper abdominal pain, and early satiety for at least 3 months before&#xD;
             screening as assessed by a physician.&#xD;
&#xD;
          2. Must have confirmed delayed gastric emptying by meeting 1 of the following criteria:&#xD;
&#xD;
               1. Confirmed by an accepted diagnostic testing method (Gastric Emptying Breath Test&#xD;
                  [GEBT], scintigraphy, or wireless motility capsule) that is documented in the&#xD;
                  participant's medical records prior to screening; OR&#xD;
&#xD;
               2. Participants without previous confirmation of delayed gastric emptying prior to&#xD;
                  screening will undergo a GEBT after they have stopped taking prohibited&#xD;
                  medications.&#xD;
&#xD;
          3. Must have an average composite ANMS GCSI-DD symptom score â‰¥2 during the 7 days before&#xD;
             randomization. The predominant symptom experienced by participants must not be&#xD;
             abdominal pain.&#xD;
&#xD;
          4. Must experience nausea: nausea subscale (of ANMS GCSI-DD) symptom score â‰¥2 at least 4&#xD;
             of 7 days or an average nausea subscale symptom score â‰¥2 during the 7 days before&#xD;
             randomization. Nausea symptoms must not be attributable to a central disorder (e.g.&#xD;
             motion sickness, glaucoma, menstrual cycles, migraine headache).&#xD;
&#xD;
          5. Has a body mass index (BMI) of â‰¥18 to â‰¤40 kg/m^2 inclusive.&#xD;
&#xD;
          6. Participant with diabetes mellitus must have glycosylated hemoglobin (HbA1c) â‰¤11% at&#xD;
             screening and before randomization.&#xD;
&#xD;
          7. Absence of gastric outlet obstruction confirmed by upper GI, computed tomography or&#xD;
             endoscopy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known secondary causes of gastroparesis including but not limited to Parkinson&#xD;
             disease, cancer, viral illness, or connective tissue diseases.&#xD;
&#xD;
          2. Predominant gastroparetic symptom is epigastric pain, diffuse abdominal pain, or pain&#xD;
             associated with bowel movement.&#xD;
&#xD;
          3. Is taking medications that affect gastric emptying including opioids, glucagon-like&#xD;
             peptide-1 analogs (e.g., exenatide, liraglutide), amylin analogs (e.g., pramlintide),&#xD;
             and cannabinoids.&#xD;
&#xD;
          4. Prior history of gastric surgery, including but not limited to gastrectomy, gastric&#xD;
             bypass, gastric banding, bariatric surgery, pyloroplasty, vagotomy, or fundoplication,&#xD;
             which has manipulated the natural anatomy of the stomach.&#xD;
&#xD;
          5. History of intra-pyloric botulinum toxin injection within 3 months of Screening or&#xD;
             currently has functioning implantable electric stimulator.&#xD;
&#xD;
          6. Nasogastric, percutaneous endoscopic gastrostomy, or percutaneous endoscopic&#xD;
             jejunostomy feeding tube or inpatient hospitalization for gastroparesis within 2 weeks&#xD;
             before the Screening Visit.&#xD;
&#xD;
          7. Required parenteral nutrition for treatment of gastroparesis within 2 months before&#xD;
             the Screening Visit.&#xD;
&#xD;
          8. Previous diagnosis of gastric bezoar (the presence of retained liquid, bile, or small&#xD;
             amounts of poorly organized food residue is permitted).&#xD;
&#xD;
          9. Poor control of diabetes within 30 days prior to randomization, including diabetic&#xD;
             ketoacidosis, hypoglycemia requiring medical intervention, admission for control of&#xD;
             diabetes or diabetic complications.&#xD;
&#xD;
         10. Elevated serum prolactin (&gt;upper limit of normal [ULN]) at Screening.&#xD;
&#xD;
         11. Has concurrent hypogonadism, current clinically significant menstrual abnormalities,&#xD;
             such as amenorrhea or oligomenorrhea, or other clinical features of hyperprolactinemia&#xD;
             such as galactorrhea or gynecomastia.&#xD;
&#xD;
         12. Has acute or chronic liver disease meeting any of the criteria described below:&#xD;
&#xD;
               -  Has an alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total&#xD;
                  bilirubin &gt;2.0 times the ULN.&#xD;
&#xD;
               -  Has pre-existing liver cirrhosis that meets Child-Pugh Class B (moderate; total&#xD;
                  score 7 to 9 points) or C (severe; total score 10 to 15 points) (see Appendix B).&#xD;
&#xD;
               -  Has acute or chronic hepatitis B or C virus infection, manifesting as one of the&#xD;
                  following at screening:&#xD;
&#xD;
               -  Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody&#xD;
                  (HBcAb). NOTE: if a participants tests negative for HBsAg, but positive for&#xD;
                  HBcAb, the participant would be eligible if the Investigator has documentation of&#xD;
                  other test results showing that the participant does not have active hepatitis B&#xD;
                  infection.&#xD;
&#xD;
               -  Participants with positive hepatitis C antibody (HCV IgG) and quantitative HCV&#xD;
                  polymerase chain reaction (PCR). HCV PCR is performed only if HCV IgG is&#xD;
                  positive.&#xD;
&#xD;
         13. Has renal impairment, defined as a lower limit of (estimated glomerular filtration&#xD;
             rate [eGFR]) &lt;30 mL/min at screening visit.&#xD;
&#xD;
         14. Has active neoplastic disease or history of neoplastic disease within 5 years of&#xD;
             screening visit (except for basal or squamous cell carcinoma of the skin or carcinoma&#xD;
             in situ of the uterine cervix that has been definitively treated with standard of care&#xD;
             approaches).&#xD;
&#xD;
         15. Uncontrolled or poorly controlled medical or psychiatric comorbidities which might&#xD;
             affect their ability to participate in the study.&#xD;
&#xD;
         16. Has known COVID-19 infection, or suspected COVID-19 infection (as assessed by the&#xD;
             investigator).&#xD;
&#xD;
         17. Signs/symptoms or history of extrapyramidal system disease and other clinically&#xD;
             relevant CNS or neuropsychiatric disease including but not limited to tardive&#xD;
             dyskinesia, neuroleptic malignant syndrome, acute dystonia, parkinsonian like&#xD;
             symptoms, severe mental depression, and history of suicide attempt.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Health Specialists of the Southeast</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GW Research</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial Connections - New Hope Research Development</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paragon Rx Clinical - Garden Grove</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute Inc.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Medical Research Associates</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISS - Conquest Clinical Research</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Foundation</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISS - Innovative Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elias Research Associates - Direct Helpers Research Center - Hialeah</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Associates</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homestead Associates in Research</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates - Crystal River</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Diabetes Associates Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaSouth Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Dade Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anchor Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute - New Port Richey</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Center</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Healthcare of Georgia - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research - Southwest Gastroenterology - Oak Lawn</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Gastroenterology Associates</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Center of Maryland</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGH Digestive Healthcare</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - West Roxbury</name>
      <address>
        <city>West Roxbury</city>
        <state>Massachusetts</state>
        <zip>02132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Western Michigan</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Associates and Endoscopy Center</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Medical Research</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources - Albuquerque</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Scientific</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Gastrointestinal Research Group</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Clinical Research</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fayetteville Gastroenterology Associates</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Digestive Diseases</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834-3761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial Management Associates</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of the Piedmont</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Partners - Center for Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research - Lynn Institute of Stillwater</name>
      <address>
        <city>Stillwater</city>
        <state>Oklahoma</state>
        <zip>74074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates - Wyomissin</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions - Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Phase Research and Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center - El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spring Gastroenterology Associates - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic Houston 1</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic Houston 2</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rio Grande Gastroenterology</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Associates in Research Therapeutics of America</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Tidewater</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiteit Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Lucas</name>
      <address>
        <city>Brugge</city>
        <state>West-vlaanderen</state>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Campus Kennedylaan</name>
      <address>
        <city>Kortrijk</city>
        <state>West-vlaanderen</state>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070 Bruxelles</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiteit Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai Memorial Hospital</name>
      <address>
        <city>Kasugai-shi</city>
        <state>Aichi</state>
        <zip>487-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya City</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meitetsu Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>451-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chubu-Rosai Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>455-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokatsu Tsujinaka Hospital</name>
      <address>
        <city>Abiko</city>
        <state>Chiba</state>
        <zip>270-1168</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuyama Shimin Hospital</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>790-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hatakeyama Clinic</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>810-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oishi Clinic</name>
      <address>
        <city>Kasuya-gun</city>
        <state>Fukuoka</state>
        <zip>811-2310</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Igarashi Internal Medicine Surgery Clinic</name>
      <address>
        <city>Koriyama City</city>
        <state>Fukushima</state>
        <zip>963-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahi University Hospital</name>
      <address>
        <city>Gifu-city</city>
        <state>Gifu</state>
        <zip>500-8523</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakamura Digestive Organ Internal Medicine Clinic</name>
      <address>
        <city>Bibai</city>
        <state>Hokkaido</state>
        <zip>072-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akakura GI Clinic</name>
      <address>
        <city>Sapporo-Shi</city>
        <state>Hokkairdo</state>
        <zip>060-0807</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Prefectural Nishinomiya Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>662-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takarazuka City Hospital</name>
      <address>
        <city>Takarazuka-shi</city>
        <state>Hyogo</state>
        <zip>665-0827</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hitachi, Ltd. Hitachinaka General Hospital</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <zip>312-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minami Akatsuka Clinic</name>
      <address>
        <city>Mito-shi</city>
        <state>Ibaraki</state>
        <zip>311-4153</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuchiura Beryl Clinic</name>
      <address>
        <city>Tsuchiura City</city>
        <state>Ibaraki</state>
        <zip>300-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Shintoukai Yokohama Minoru Clinic</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takatsuki Red Cross Hospital</name>
      <address>
        <city>Takatsuki-shi</city>
        <state>Osaka</state>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Kumagaya General Hospital</name>
      <address>
        <city>Kumagaya</city>
        <state>Saitama</state>
        <zip>360-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakasa Clinic</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-1151</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital Koga Hospital</name>
      <address>
        <city>Yaizu</city>
        <state>Shizuoka</state>
        <zip>425-0088</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimokitazawa Tomo Clinic</name>
      <address>
        <city>Setagaya-Ku</city>
        <state>Tokyo</state>
        <zip>155-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morinaga Ueno Clinic</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-0863</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ijinkai Takeda General Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>601-1495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai General Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Kamata Clinic</name>
      <address>
        <city>Saitama</city>
        <zip>330-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology and Internal Medicine, Oizumi Medical Clinic</name>
      <address>
        <city>Yamagata</city>
        <zip>990-0832</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITAMED Galaj i Cichomski spolka jawna</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Clw-Med Aneta Cichomska i Joanna uka-Wendrowska sp.j.</name>
      <address>
        <city>Grudziadz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bodyclinic</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-332</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Lukamed Joanna Luka</name>
      <address>
        <city>Chojnice</city>
        <state>Pomorskie</state>
        <zip>89-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej - Witamed Poradnia Diabetolo</name>
      <address>
        <city>Kielce</city>
        <state>Swietokrzyskie</state>
        <zip>25-035</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b60354db2bf003ab4a062</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

